Novo Nordisk A/S EBITDA margin
What is the EBITDA margin of Novo Nordisk A/S?
The EBITDA margin of Novo Nordisk A/S is 43.08%
What is the definition of EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin of companies in the Miscellaneous sector on LSE compared to Novo Nordisk A/S
What does Novo Nordisk A/S do?
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Companies with ebitda margin similar to Novo Nordisk A/S
- Sinovac Biotech has EBITDA margin of 42.99%
- Sheng Yuan has EBITDA margin of 42.99%
- Sotera Health Co has EBITDA margin of 42.99%
- Lifestyle International has EBITDA margin of 43.04%
- Enable Midstream Partners LP has EBITDA margin of 43.05%
- Roper Technologies has EBITDA margin of 43.07%
- Novo Nordisk A/S has EBITDA margin of 43.08%
- Wyndham Hotels & Resorts Inc has EBITDA margin of 43.08%
- First Internet Bancorp has EBITDA margin of 43.10%
- IHS Ltd has EBITDA margin of 43.16%
- Brookfield Infrastructure Partn has EBITDA margin of 43.16%
- UMH Properties Inc has EBITDA margin of 43.16%
- Atlanta has EBITDA margin of 43.17%